---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-106913"
form_type: "8-K"
ticker: "CLYM"
cik: "0001768446"
company_name: "Climb Bio, Inc."
filed_at: "2025-08-12T23:59:59+00:00"
generated_at: "2026-05-17T14:44:10.671007+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Climb Bio Q2 cash $187.4M, R&D $6.6M; budoprutug trials underway; new CMO

## Summary
- Cash and marketable securities $187.4M as of June 30, 2025; cash runway expected through 2027.
- R&D expenses $6.6M in Q2 2025 vs $1.0M in Q2 2024; no acquired IPR&D expense in 2025.
- Budoprutug ITP and SLE trials dosing patients; pMN Phase 2 to initiate; SC formulation Phase 1 data expected H1 2026.
- CLYM116 investor event September 2025 with preclinical data; IND/CTA for IgAN expected H2 2025.
- Edgar D. Charles, M.D., MSc appointed CMO, joining from Bristol Myers Squibb in June 2025.

## SEC filing metadata
- accession: 0000950170-25-106913
- form_type: 8-K
- ticker: CLYM
- cik: 0001768446
- company_name: Climb Bio, Inc.
- filed_at: 2025-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1768446/000095017025106913/0000950170-25-106913-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1768446/000095017025106913/clym-20250812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-106913
- JSON: https://secwatch.observer/filing/0000950170-25-106913.json
- Plain text: https://secwatch.observer/filing/0000950170-25-106913.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.